Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BTK C481S |
| Therapy | Ibrutinib |
| Indication/Tumor Type | chronic lymphocytic leukemia |
| Response Type | resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BTK C481S | chronic lymphocytic leukemia | resistant | Ibrutinib | Preclinical - Patient cell culture | Actionable | In a preclinical study, primary chronic lymphocytic leukemia cells derived from patients who acquired BTK C481S following Imbruvica (ibrutinib) treatment demonstrated resistance to Imbruvica (ibrutinib) in culture (PMID: 30093506). | 30093506 |
| BTK C481S | chronic lymphocytic leukemia | resistant | Ibrutinib | Clinical Study - Cohort | Actionable | In a clinical study, BTK C481S was identified as an acquired mutation in patients with chronic lymphocytic leukemia who relapsed while on Imbruvica (ibrutinib), and was demonstrated to confer resistance to Imbruvica (ibrutinib) in preclinical studies (PMID: 24869598). | 24869598 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (24869598) | Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. | Full reference... |
| (30093506) | The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation. | Full reference... |